{"entity":{"id":"nct05706779","kind":"trial","name":"Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer","aka":["NEORAF"],"tldr":"A phase 2 trial of cetuximab in colorectal cancer, run by Federation Francophone de Cancerologie Digestive, now recruiting.","summary":"Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer is a phase 2, interventional study registered as NCT05706779 by Federation Francophone de Cancerologie Digestive, with a registry enrolment figure of 30 participants, started 2023-02-13 and due to reach its primary completion in 2026-12-30. Interventions recorded: Encorafenib Oral Capsule + Cetuximab. Conditions listed: Colorectal Cancer; BRAF V600E Mutation Positive. Primary outcome: To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010). Colorectal eligibility wording from the registry: \"* Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E determined in a biopsy specimen and resectable after CT-scan assessment\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05706779","url":"https://clinicaltrials.gov/study/NCT05706779"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","braf-v600e-colorectal"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["cetuximab"],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05706779","phase":"2","setting":"Combination of Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With Braf v600e-mutates Localised Colon or Upper Rectum Cancer (Neoraf Study)","sponsor":"Federation Francophone de Cancerologie Digestive","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05706779/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}